Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

7.430 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

February 23, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

February 23, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results

February 09, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

January 12, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

December 16, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

November 19, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

November 09, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

November 07, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 05, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

November 03, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

October 22, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

October 09, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025

October 07, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 25, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 06, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

August 06, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

July 31, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

July 24, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

July 22, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 20, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 09, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 07, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

April 30, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

April 24, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

March 13, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

February 26, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

February 19, 2025

From Vir Biotechnology, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.